作者
Gang Chen, Alexander C Huang, Wei Zhang, Gao Zhang, Min Wu, Wei Xu, Zili Yu, Jiegang Yang, Beike Wang, Honghong Sun, Houfu Xia, Qiwen Man, Wenqun Zhong, Leonardo F Antelo, Bin Wu, Xuepeng Xiong, Xiaoming Liu, Lei Guan, Ting Li, Shujing Liu, Ruifeng Yang, Youtao Lu, Liyun Dong, Suzanne McGettigan, Rajasekharan Somasundaram, Ravi Radhakrishnan, Gordon Mills, Yiling Lu, Junhyong Kim, Youhai H Chen, Haidong Dong, Yifang Zhao, Giorgos C Karakousis, Tara C Mitchell, Lynn M Schuchter, Meenhard Herlyn, E John Wherry, Xiaowei Xu, Wei Guo
发表日期
2018/8/16
期刊
Nature
卷号
560
期号
7718
页码范围
382-386
出版商
Nature Publishing Group UK
简介
Tumour cells evade immune surveillance by upregulating the surface expression of programmed death-ligand 1 (PD-L1), which interacts with programmed death-1 (PD-1) receptor on T cells to elicit the immune checkpoint response,. Anti-PD-1 antibodies have shown remarkable promise in treating tumours, including metastatic melanoma, –. However, the patient response rate is low,. A better understanding of PD-L1-mediated immune evasion is needed to predict patient response and improve treatment efficacy. Here we report that metastatic melanomas release extracellular vesicles, mostly in the form of exosomes, that carry PD-L1 on their surface. Stimulation with interferon-γ (IFN-γ) increases the amount of PD-L1 on these vesicles, which suppresses the function of CD8 T cells and facilitates tumour growth. In patients with metastatic melanoma, the level of circulating exosomal PD-L1 positively correlates with that …
引用总数
201820192020202120222023202417233354467417417246